111, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a YI research report →
Price Chart
About the company
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels.
- CEO
- Junling Liu
- IPO
- 2018
- Employees
- 1,063
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on YI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.99M
- P/E
- -1.74
- PEG
- 0.05
- P/S
- 0.02
- P/B
- -1.60
- EV/EBITDA
- -3.47
- Div Yield
- 0.00%
- Gross Margin
- 5.73%
- Op Margin
- -0.48%
- Net Margin
- -0.91%
- ROE
- 23.64%
- ROIC
- -11.30%
Latest fiscal year · YoY change
- Revenue
- $12.21B-15.2%
- Gross Profit
- $703.70M-15.1%
- Op Income
- $-10,028,129
- Net Income
- $-16,843,257+74.0%
- EPS
- $-7.42+1.3%
- OCF Growth
- -54.7%
- FCF Growth
- -53.7%
- 52W High
- $11.17
- 52W Low
- $2.48
- 50D MA
- $3.57
- 200D MA
- $5.08
- Beta
- 0.67
- RSI (14)
- 36
- Avg Volume
- 11.46K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
111 ended 2024 with its first-ever annual operating profit and positive operating cash flow, while revenue declined and management emphasized AI, supply-chain expansion, and continued cost discipline.· March 20, 2025
- FY2024 operating income turned positive for the first time at RMB2.1 million, versus a RMB350.1 million loss in 2023; non-GAAP operating income was RMB22.3 million versus a RMB123.9 million loss last year.
- Full-year net revenues were RMB14.4 billion, down 3.7% YoY, while gross segment profit was RMB829.2 million, down 2.3% YoY.
- Q4 net revenues were RMB3.8 billion and gross segment profit was RMB202.5 million; both declined YoY, but operating expenses fell sharply.
- The company said it generated RMB263 million of positive operating cash flow for the full year and ended with RMB518.3 million of cash and equivalents, restricted cash, and short-term investments.
- Management highlighted AI-driven forecasting, shared inventory, and the Kunpeng logistics network as key enablers of lower costs and better fulfillment efficiency.
Q4 2024 net revenues were RMB3.8 billion and gross segment profit was RMB202.5 million, both down 6.3% and 5.5% YoY, respectively. Q4 total operating expenses fell 50.1% to RMB209.8 million, or 5.5% of net revenues; non-GAAP loss from operations was RMB2.3 million, and non-GAAP net loss attributable to ordinary shareholders was RMB14.8 million. For full-year 2024, net revenues were RMB14.4 billion and gross segment profit was RMB829.2 million, down 3.7% and 2.3% YoY, respectively. Full-year operating expenses decreased 31% to RMB827.1 million, operating income was RMB2.1 million versus a RMB351 million loss in 2023, non-GAAP operating income was RMB22.3 million, and the company generated RMB263 million of positive operating cash flow. Cash and cash equivalents, restricted cash, and short-term investments were RMB518.3 million as of December 31, 2024. Management did not provide formal 2025 revenue or EPS guidance on the call.
CEO Junling Liu framed 2024 as a difficult year for the industry, citing macro pressure, healthcare reforms, and weak consumer spending, but said 111 still reached a major milestone by delivering its first operating profit and positive cash flow. He emphasized that the company’s strategy is centered on digitization, AI, and a decentralized inventory model to improve efficiency, expand assortment, and support competitive pricing. His tone was confident and resilient, with repeated references to 111’s ability to compete through technology and operational execution.
CFO Luke Chen focused on the financial turnaround and expense discipline. He said Q4 operating expenses fell to 5.5% of revenue from 10.2% a year ago, with sales and marketing at 2.0%, G&A at 0.5%, and technology at 0.4% of net revenue; for the full year, operating expenses were 5.7% of revenue versus 8.0% in 2023. He also highlighted RMB518.3 million of cash and equivalents plus short-term investments, RMB263 million of annual operating cash flow, and an update on RMB1.08 billion of outstanding redemption-related liabilities, noting agreements or commitment letters covering approximately 97% of that amount to reschedule repayments. He said the company is confident it is on a path toward sustainable profitability.
Analysts pressed management on how the weak macro environment affected the business, what drove gross margin improvement, and how the company cut operating expenses so sharply. Management replied that the key drivers were better operating leverage, staffing and expense optimization, a more efficient fulfillment network, and a technology-heavy operating model. Questions also focused on 2025 growth, AI investment, and whether AI will become a new business line; management said AI will be embedded across pricing, assortment, supply chain, and customer service, but did not give a budget number. On logistics and fulfillment, management said more franchise fulfillment centers and the Kunpeng network should reduce delivery costs and improve regional fulfillment.
The clearest positive is that 111 reached first-ever annual operating profitability and positive operating cash flow despite a tough market. Management also pointed to tangible efficiency gains from AI, shared inventory, and the Kunpeng logistics network, including lower stock-out rates, faster fulfillment, and a much leaner cost structure. If those initiatives keep scaling, the company believes it can support profitability while still growing its platform.
Revenue still declined in both Q4 and FY2024, reflecting a weak market and policy-related pressure on pharmacies and consumer spending. Management also noted ongoing uncertainty around healthcare reform execution and the transition period for new reimbursement and medical insurance policies. In addition, the company still has RMB1.08 billion of redemption-related liabilities, and while most have been rescheduled, this remains a financial overhang.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.2%
- Shares Outstanding
- 8.74M
- Float Shares
- 8.58M
of shares held by institutions
8 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 17.34K | ▲ 17.34K |
| Renaissance Technologies LLC | 12.91K | ▼ 100 |
| Serenus Wealth Advisors, LLC | 4.32K | 0 |
| Ubs Group AG | 1.60K | ▲ 1.50K |
| Sbi Securities Co., Ltd. | 149 | ▲ 5 |
| Morgan Stanley | 113 | 0 |
| Jpmorgan Chase & Co | 47 | ▼ 5 |
| Rhumbline Advisers | 22 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Chen Yang Luke | other | 413,168 |
| May 26, 26 | Chen Yang Luke | sell | 1,440 |
| May 27, 26 | Chen Yang Luke | sell | 3,400 |
| Jun 12, 26 | Chen Yang Luke | sell | 49,920 |
| Jun 15, 26 | Chen Yang Luke | sell | 44,000 |
| Sep 23, 26 | Chen Yang Luke | sell | 44,000 |
| Sep 28, 26 | Chen Yang Luke | sell | 38,120 |
| May 11, 26 | Chen Yang Luke | other | 54,759 |
| Sep 8, 23 | Chen Yang Luke | other | 126,295 |
| Sep 23, 26 | Chen Yang Luke | sell | 44,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our YI coverage
Recent articles, reports, and earnings notes.
No research on YI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate YI report →111, Inc. Announces Establishment of the Special Committee
gurufocus.com · Sep 28
111, Inc. Announces Establishment of the Special Committee
prnewswire.com · Sep 28
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
prnewswire.com · Sep 17
111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
gurufocus.com · Sep 17
111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
prnewswire.com · Sep 17
Critical Review: 111 (NASDAQ:YI) and SBC Medical Group (NASDAQ:SBC)
defenseworld.net · Sep 16
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
gurufocus.com · Jun 4
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
prnewswire.com · Jun 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.